Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation

Dutta, Rimlee; Kumar, Arvind; Julka, Pramod Kumar; Mathur, Sandeep; Kaushal, Seema; Kumar, Rakesh; Jindal, Tarun; Suri, Vaishali

doi:10.1510/icvts.2010.237651

Cited by 29 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thymic carcinoids often behave aggressively and present as advanced disease due to the invasion of adjacent mediastinal structures, local recurrence or metastases. 1 Images of thymic carcinoids usually demonstrate a large anterior mediastinal mass. Although only a few reports describing the imaging features of thymic carcinoid have been published, these lesions have been described as masses indistinguishable from thymomas.…”

Section: Introductionmentioning

confidence: 99%

CT and MRI findings of thymic carcinoid

Shimamoto

Ashizawa

Kido

et al. 2017

The British Journal of Radiology

View full text Add to dashboard Cite

Objective: To evaluate the CT and MRI findings of thymic carcinoid and to compare these findings with previously published findings of thymoma. Methods: 11 cases of pathologically proven thymic carcinoid were reviewed retrospectively. Three patients had typical carcinoid, and eight patients had atypical carcinoid. The characteristics of the tumours and related thoracic abnormalities were assessed in each case on CT and/or MRI by two chest radiologists. The final decisions on the findings were reached by consensus. Results: Thymic carcinoids were more likely to have a large mass (ranging from 18 to 105 mm), irregular contours (n 5 8), heterogeneous intensity on T 2 weighted images (n 5 6; eight patients underwent MRI), heterogeneous enhancement (n 5 9) and local invasion (n 5 7).A necrotic or cystic component was identified in seven patients (one typical carcinoid and six atypical carcinoids). Lymphadenopathy was seen in four patients. Septum, capsule, haemorrhage and calcification were seen in three patients, two patients, two patients and one patient, respectively, with atypical carcinoid. Conclusion: Thymic carcinoids tend to have a high prevalence of large masses, irregular contours, heterogeneous intensity on T 2 weighted images, heterogeneous enhancement and local invasion on CT and/or MRI. A necrotic or cystic component is often seen in atypical carcinoid. Advances in knowledge: Radiologic features of thymic carcinoid mimic those of high-risk thymomas and/or thymic carcinomas.

show abstract

Section: Introductionmentioning

confidence: 99%

CT and MRI findings of thymic carcinoid

Shimamoto

Ashizawa

Kido

et al. 2017

The British Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…At the time of diagnosis, about 75% of tumors show an infiltration of adjacent organs or distant metastases e.g., to spine and liver (51,59).…”

Section: Lcnec (Icd-o 8013/3)mentioning

confidence: 99%

Neuroendocrine tumors of the thymus and mediastinum

Bohnenberger¹,

Dinter²,

König³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Neuroendocrine tumors of the thymus (tNET) and mediastinum are very rare neoplasms with scarce available data. All subtypes [typical and atypical carcinoid tumors (TC and AC), large cell neuroendocrine and small cell carcinoma (SCC)] observed elsewhere in the body occur also in the mediastinum and show only few if any organ-specific morphological differences. Although all available data suggest that the broad principles that govern the biology (and hence) the classification of these tumors in general apply also to tNET, there are a few noteworthy peculiarities related e.g., to risk factors, relative frequency and also to molecular genetic features. In this review, we will briefly summarize current knowledge on tNET with a special emphasis on shared and private features in comparison e.g., with pulmonary NET, which have traditionally been regarded the next closely related NET group.

show abstract

“…Definitionsgemäß wird mindestens einer der neuroendokrinen Marker in mehr als 50 % der Tumorzellen exprimiert. Teilweise kann CD117 positiv sein, wobei CD5 immer negativ ist [5,8].…”

Section: Immunhistochemieunclassified